GlassScriptPhysician profile
Philip J Wilson
NPI 1962842476
$3,814.53
in general payments reported to CMS, 2019-2025
27 companies · $655 in 2025
The $655 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $63.48 · 2021: $850 · 2022: $722 · 2023: $673 · 2024: $573 · 2025: $655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,008.59 | 2019-2025 | Hydrus Microstent, Argos, Clareon |
| Sight Sciences, INC. | $321.87 | 2021-2022 | |
| Allergan, INC. | $293.40 | 2019-2022 | |
| Ivantis, INC | $226.23 | 2020-2021 | |
| Abbvie INC. | $221.95 | 2022-2025 | Durysta |
| Johnson & Johnson Surgical Vision, INC. | $212.61 | 2022-2025 | Tecnis Iol, Catalys System, Tecnis Iol |
| Regeneron Healthcare Solutions, INC. | $164.77 | 2022-2025 | Eylea, Eylea Hd |
| New World Medical,INC. | $160.92 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $127.81 | 2022-2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $117.72 | 2023-2024 | Syfovre |
| Biogen, INC. | $114.97 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $114.47 | 2022-2023 | |
| Glaukos Corporation | $97.77 | 2020-2025 | Idosetr, Istent Infinite, Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb Americas INC. | $86.17 | 2022-2025 | Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $80.98 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $80.88 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.89 | 2021 | |
| Dompe US, INC. | $73.09 | 2024-2025 | Oxervate |
| Thea Pharma INC. | $67.84 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $36.13 | 2022 | |
| Genentech USA, INC. | $26.73 | 2025 | Vabysmo |
| Rayner Intraocular Lenses Limited | $19.85 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Horizon Therapeutics Plc | $19.04 | 2023 | Tepezza |
| Oyster Point Pharma, INC. | $17.83 | 2022 | |
| Johnson & Johnson Vision Care, INC. | $15.33 | 2024 | |
| Amarin Pharma, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.